Back To Education Zone

touchCONGRESS Expert Interviews

Should we use third-generation TKIs up front in EGFR+ NSCLC?



Watch a series of internationally renowned clinical specialists discuss key clinical data of interest from the ESMO Congress 2019 in Barcelona, Spain, 27 September to 1 October 2019 and the ESMO Asia Congress 2019 in Singapore, 22–24 November 2019.

The potential implications of these data for optimizing clinical outcomes for patients with EGFR+ NSCLC are explored from both global and regional perspectives.

The information in this activity is intended for oncologists and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objectives

After watching this touchCONGRESS Expert Interviews, you should be able to:

  • Recall significant data for 3rd-generation EGFR TKIs in EGFR+ NSCLC
  • Recognize differences between the available EGFR TKIs in terms of efficacy and safety
  • Describe real-world evidence with 3rd-generation EGFR TKIs and the issues surrounding them

Please feed back on these touchEXPERT INTERVIEWS on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).